top of page
  • Writer's pictureLaurent DECORY

Dr Laurent Décory, BlueJet Consulting Managing Director, joins Aurealis Therapeutics as COO

Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that Mr. Laurent Décory, who joined the Board of Directors in June 2020, has accepted to join the company management team as Chief Operating Officer. Laurent will be in charge of Business Development, Health Economics, Marketing & Communication and Scientific Advisory activities. The timing of the nomination of Dr. Décory occurs in parallel with the company successfully completing an exclusive license and collaboration agreement with XBiome, for the clinical development and commercialization of AUP-16, Aurealis investigational therapy for Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory diseases, in greater China.

Laurent brings to the company substantial experience and commercial leadership both in the Advanced Wound Care (AWC, Medtech) and Pharmaceutical industries. On top of being a board member for the past two years, Laurent is the Managing Director of the company BlueJet Consulting, and was previously Head, Global Commercial Excellence of Essity Health and Medical. Prior to that, Laurent was also Senior Vice-President, Global Commercial Excellence at BSN Medical in Hamburg. Previously, he held a variety of senior management and director roles at Takeda and Nycomed in Zurich, and Sanofi-Aventis and predecessor companies in Paris. Laurent has MSc. and PhD in Neurosciences & Pharmacology from University of Bordeaux and holds MBA from the ESSEC Business School, Paris.

“We have enjoyed having Laurent as a board member and we are thrilled to have him joining our management team,” said Juha Yrjänheikki, CEO of Aurealis Therapeutics. “His vast commercial and strategic experience and leadership combined with scientific drive and understanding in the Medtech and Pharma industry are unique and impressive. We look forward to his contributions to the company as we are advancing in our phase 2 patient trials and need to think more and more about the commercial end-product and partnering/co-development.”

“I am very excited to join Aurealis Therapeutics as Chief Operating Officer,” said Dr. Décory. “Chronic wounds represent a major unmet medical need and a massive burden to patients and society. I look forward to working with the whole team, the Scientific Advisory Board, and the Board members to make this game-changing technology better known and closer to commercialization. Moreover, I share the passion within the team to expand AUP-16 usage to other inflammatory indications as well”


bottom of page